Fresenius appoints Mahl. Fresenius stock sits 14.82 percent below its high.

Published on 10/21/2026 at 09:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mahl starts November 1, 2026. Hennicken's contract runs to 2032. Fresenius stock costs EUR 45.11 on October 21, 2026, 0.24 percent above EUR 45.00.

Leadership and earnings milestones

Fresenius appointed Dr. Marc-Alexander Mahl to its board on October 15, 2026.
Second-quarter 2026 revenue rose 6.00 percent to EUR 5.864 billion.
Fresenius stock trades at EUR 45.11 at 9:17 a.m. CEST at Lang & Schwarz on October 21, 2026, 0.24 percent above the Xetra close of October 20, 2026.
Sara Hennicken's contract now runs until 2032.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) was trading at EUR 45.11 at Lang & Schwarz on October 21, 2026, at 9:17 a.m. CEST, 0.24 percent above the Xetra close of October 20, 2026. On October 15, 2026, Fresenius said Dr. Marc-Alexander Mahl would join the Management Board effective November 1, 2026, succeeding Pierluigi Antonelli and taking responsibility for Fresenius Kabi.

Leadership changes set the next phase

The management decision also extends Chief Financial Officer Sara Hennicken's contract for five years, taking it to 2032. The company said Sebastien Guery would assume overall responsibility for Nutrition as a standalone business unit. The changes place Pharma, Nutrition and the wider Kabi portfolio under a revised leadership structure.

Three milestones shape the story

Fresenius sold 7.8 million Fresenius Medical Care shares for about EUR 300 million on August 20, 2026. The company signed and completed the acquisition of the remaining 45.00 percent of mAbxience for up to EUR 750.00 million on September 30, 2026. The October 15, 2026 management announcement then put the next leadership step on the calendar. These three events show a company combining capital allocation with portfolio control and operating changes.

What does the operating picture show?

Fresenius reported second-quarter 2026 revenue of EUR 5.864 billion, up 6.00 percent from EUR 5.571 billion in the second quarter of 2025. Core net income rose 14.00 percent to EUR 470 million from EUR 412 million, while core earnings per share increased 14.00 percent to EUR 0.83. These figures came from the company's investor-relations information for the second quarter of 2026.

The same report showed EBIT of EUR 719 million, up 10.00 percent from EUR 654 million in the second quarter of 2025. Kabi revenue reached EUR 2.244 billion, up 7.00 percent, while Helios revenue increased 5.00 percent to EUR 3.526 billion. The operating data give the board changes a financial backdrop rather than making them a standalone personnel story.

Dates for the next steps

Mahl is scheduled to take office on November 1, 2026, and Fresenius is scheduled to publish its third-quarter 2026 financial report on November 4, 2026, according to the company's investor-relations calendar.

Stock stays below its yearly high

At EUR 45.11, the stock stood 14.82 percent below its 52-week high of EUR 52.96 and above its 52-week low of EUR 35.11. Market capitalization was EUR 25.5 billion as of October 21, 2026. The next results date will provide the first scheduled test of the revised leadership setup.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.